

REMARKS/ARGUMENTS

The Restriction action dated 2 August 2006 required election between claim groups I-II. Applicants herein elect claim group I, including claims 1-29. Claims 3-4, 6, 8, 10, 13-14, 21-22, 24-26 and 30-31 are cancelled without prejudice or disclaimer.

In response to the election requirement, applicants elect the polypeptide of SEQ ID NO:2. Claims 1, 2, 5, 7, 9, 11-12, 15-20, 23 and 27-29 read upon the elected species.

Conclusion

It is believed that this document is fully responsive to the Restriction requirement raised in the Restriction action dated 21 August 2006. In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged.

Fees

It is believed that no fee is due with the submission of this response. In the event it is determined that a fee is due, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650 for the amount of that fee.

Respectfully submitted



Valeta Gregg, Ph.D., Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 593-1077 (direct)